ANI Pharmaceuticals (ANIP) Fundamental Analysis: Revenue, Earnings & Valuation

5.10 / 10

Netural

Fundamental metrics average 5.1/10, yielding a neutral rating. Strengths include inventory turnover (2.44) and low cost‑of‑sales ratio (38.64%), while accounts‑receivable turnover (3.51) lags. Overall, the fundamentals are modest with selective upside.

Analysis Checks(9/10)

Revenue-MV

Value0.10

Score2/3

Weight22.11%

1M Return6.87%

Total operating revenue (YoY growth rate %)

Value43.78

Score2/3

Weight1.39%

1M Return0.58%

Inventory turnover ratio

Value2.44

Score2/3

Weight-1.64%

1M Return-0.66%

Accounts receivable turnover ratio

Value3.51

Score1/3

Weight-3.69%

1M Return-1.57%

PB-ROE

Value0.12

Score3/3

Weight37.73%

1M Return12.56%

Income tax / Total profit (%)

Value18.22

Score2/3

Weight9.03%

1M Return3.20%

Fixed assets turnover ratio

Value14.80

Score3/3

Weight1.95%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value5.78

Score2/3

Weight-1.65%

1M Return-0.73%

Cost of sales ratio (%)

Value38.64

Score3/3

Weight2.06%

1M Return0.79%

Asset-MV

Value-0.55

Score2/3

Weight32.72%

1M Return9.91%

Is ANIP undervalued or overvalued?

ANIP scores 5.10/10 on fundamentals and holds a Fair valuation at present. Backed by its 15.93% ROE, 8.87% net margin, 21.29 P/E ratio, 3.04 P/B ratio, and 436.54% earnings growth, these metrics solidify its Netural investment rating.